Clinical Trials Logo

Pancreatic Ductal Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Ductal Adenocarcinoma.

Filter by:
  • Recruiting  
  • « Prev · Page 10

NCT ID: NCT03076372 Recruiting - Ovarian Cancer Clinical Trials

A Study Evaluating MM-310 in Patients With Solid Tumors

Start date: February 22, 2017
Phase: Phase 1
Study type: Interventional

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.

NCT ID: NCT02929797 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

AKT
Start date: August 2016
Phase: Phase 0
Study type: Interventional

A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.

NCT ID: NCT02926183 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Study of NAC of GA Therapy for Patients With BRPC

Start date: October 2016
Phase: Phase 2
Study type: Interventional

Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. Therefore, it was decided to consider the balance of safety and efficacy on survival time as a preoperative chemotherapy, the investigators use the NAC-GA regimen includes only two cycles (three times weekly and one week rest) of GA regimen.

NCT ID: NCT02757859 Recruiting - Cholangiocarcinoma Clinical Trials

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Start date: April 27, 2016
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well high volume washing of the abdomen works in increasing survival after surgery in patients with pancreatic cancer that can be removed by surgery. High volume washings may remove free floating cancers present after surgery and help prolong survival in patients with pancreatic cancer.

NCT ID: NCT01983410 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Start date: November 4, 2013
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.

NCT ID: NCT01879878 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]

POUDER
Start date: December 2013
Phase: N/A
Study type: Interventional

The goal of the POUDER trial is to determine the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced pancreatic ductal adenocarcinoma that receive palliative chemotherapy.

NCT ID: NCT01676259 Recruiting - Pancreatic Cancer Clinical Trials

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

PROTACT
Start date: March 7, 2018
Phase: Phase 2
Study type: Interventional

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - ORR at 6 months.